Welcome to Accentedge Health
In Pursuit of a Future Without Fatal Cancer
Innovation Leaders Summit 2021 Winner
Digital Biomarker Cancer Detection · Tokyo, Japan
“Cancer treatment is too painful, too expensive, and too ineffective because the focus of the care is on the END and NOT THE BEGINNING of the disease.”
— Syed Alam, Founder & CEO, Accentedge Health
Our Company
A Company on the Forefront of Early Cancer Detection
We believe that the key to defeating cancer lies in understanding it from every angle. Our team of world-class researchers is dedicated to unraveling the mysteries of cancer at the molecular level — identifying new targets for treatment and uncovering the complex mechanisms that drive cancer progression.
Early Detection, Not Late Intervention
We shift the focus from end-stage treatment to early-stage detection — where AI has the greatest power to save lives.
Molecular-Level Understanding
Through cutting-edge genomic and multiomics studies, we uncover the deep biological signals that cancer leaves behind long before symptoms appear.
Global Access to Breakthrough Science
Headquartered in Chicago with a presence in Washington, DC — and built on scalable cloud infrastructure accessible anywhere in the world.
Trusted by Government & Industry
Our clients include leading pharmaceutical companies and the United States Federal Government — validating our technology at the highest levels.
Introducing ABCD
AI Biomarker Cancer Detection — Our Foundational AI Model
ABCD is Accentedge Health’s breakthrough foundational AI model for the early detection and classification of cancer. Using deep learning, radiomics, and an integrated multiomics engine, ABCD achieves up to 93% accuracy across multiple cancer types — giving clinicians a faster, more reliable path to diagnosis.
- Accepts digital pathological images or multiomics data as input
- AI-powered feature extraction and automated tumor classification
- Up to 93% validated accuracy on multi-class cancer datasets
- Cloud-native — accessible globally on any device
- Reports exportable to PDF for clinical workflow integration
- Continuously learning model — improves with every case
- Fully compliant with global data privacy regulations
Introducing ABCD
Digital Input
Pathological image or multiomics data submitted
AI Examination
Cloud model extracts and analyzes tumor features
Automated Classification
Deep learning assigns tumor class and labels
Clinical Report
Detailed report delivered to any device or PDF
Validated testing accuracy on thousands of multi-class tumor image datasets
How It Works
From Sample to Diagnosis in Minutes
Identify Patient
Any patient presenting with potential tumor growth is eligible for ABCD analysis.
Submit Data
Clinical staff submits a digital pathological image or multiomics sample through the platform.
AI Analysis
ABCD's deep learning engine analyzes the data and extracts key tumor features in real time.
Classification
The model classifies the tumor type — benign or malignant — with up to 93% accuracy.
Clinical Report
A detailed report is delivered instantly to any device, enabling informed treatment decisions.
Integrated Multiomics
Six Biological Layers. One Unified Picture.
🧬
Radiomics
🔬
Genomics
🔗
Transcriptomics
⚗️
Metabolomics
Quantitative feature extraction from pathological images — analyzing tumor size, position, shape, and texture to build a precise imaging profile.
🧫
Proteomics
🔭
Glycomics
Recognition & Partnerships
Validated at the Highest Levels
🏆
Innovation Leaders Summit 2021 Winner
🏥
Leading Comprehensive Cancer Center
🏛️
US Federal Government Client
Who We Serve
Built for Every Corner of Healthcare
🩺
Clinicians & Radiologists
🔬
Research Institutions
💊
Pharmaceutical Companies
Analyzes RNA and other genetic material beyond the genome. Transcriptomic machine learning predicts cancer status and enables differential diagnosis without requiring expert manual input.